MeiraGTx, a gene therapy company headquartered in New York City’s burgeoning biotech corridor, has successfully raised $100 million in a new funding round. This capital infusion comes shortly after the company reacquired the rights to an experimental eye treatment from pharmaceutical giant Johnson & Johnson. The move positions MeiraGTx to accelerate regulatory approval efforts for the therapy in both the U.S. and European markets.

The eye drug, developed to address a specific genetic retinal disease, represents a key asset for MeiraGTx as it aims to establish a foothold in the competitive gene therapy space. The reacquisition from J&J, which had previously licensed the drug, signals MeiraGTx’s commitment to fully advancing the product through late-stage clinical trials and eventual market launch.

Located in Manhattan’s growing life sciences hub, MeiraGTx is leveraging New York City’s expanding ecosystem of biotech talent and investors. The fresh capital will enable the company to ramp up clinical development activities, regulatory submissions, and manufacturing capabilities necessary to bring the therapy to patients suffering from vision loss.

Industry analysts note that MeiraGTx’s strategic decision to bring the program back in-house could streamline development timelines and increase potential returns. With regulatory agencies in the U.S. Food and Drug Administration and the European Medicines Agency reviewing gene therapies more closely, the company is poised to benefit from a clearer pathway to approval.

This fundraising milestone underscores New York City’s growing prominence as a hub for cutting-edge biotech innovation, attracting startups and investors eager to develop transformative treatments. For local residents and the broader medical community, success by firms like MeiraGTx offers hope for novel therapies that address unmet medical needs.

Editorial Transparency. A first draft of this story was produced with AI-assisted writing tools, then reviewed for accuracy and tone by the named editor before publication. More on our process: Editorial Policy.